Some cardiac metabolic and haemodynamic alterations due to adrenergic beta-receptor blockade.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D004285:Dogs; D004983:Ethanolamines / Q000494:pharmacology; D005260:Female; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D010313:Partial Pressure; D010477:Perfusion; D010656:Phenylephrine; D010909:Pituitary Hormones, Posterior / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D012110:Reserpine / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D010909:Pituitary Hormones, Posterior; D010656:Phenylephrine; D012110:Reserpine; D011433:Propranolol